002365 永安药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1761.1303.106-0.6157.228
总资产报酬率 ROA (%)1.9600.9982.653-0.5165.959
投入资产回报率 ROIC (%)2.1491.1042.985-0.5916.975

边际利润分析
销售毛利率 (%)25.32416.91619.99225.86932.935
营业利润率 (%)10.4041.3608.6950.58110.421
息税前利润/营业总收入 (%)11.3651.2477.319-0.0879.034
净利润/营业总收入 (%)7.5900.9187.118-2.9219.075

收益指标分析
经营活动净收益/利润总额(%)101.070-81.77756.619120.148114.979
价值变动净收益/利润总额(%)10.181298.38962.250616.8743.425
营业外收支净额/利润总额(%)-1.218-7.815-2.9256.6670.430

偿债能力分析
流动比率 (X)5.2485.6524.8274.7174.192
速动比率 (X)4.7945.2074.4504.4463.668
资产负债率 (%)10.4039.93911.54612.73213.249
带息债务/全部投入资本 (%)0.6780.5742.4892.3621.947
股东权益/带息债务 (%)14,588.98617,188.1383,882.8294,048.6294,947.520
股东权益/负债合计 (%)863.720908.463748.007663.854628.128
利息保障倍数 (X)10.463-86.467-6.4810.123-6.309

营运能力分析
应收账款周转天数 (天)49.72262.24068.54862.61249.580
存货周转天数 (天)41.00751.01043.82554.78154.209